

# **Rôle de FXR dans la réPLICATION des virus des hépatites B et C**

**Patrice André, MD, PhD**

**Inserm U851  
Université Claude Bernard Lyon1  
Hospices Civils de Lyon  
Lyon, France**

**Journées Nationales d'Infectiologie  
10-12 juin 2009  
Lyon**



# Nuclear receptors and virus replication



DNA virus


Hepatitis B virus,  
a well known example of virus whose tropism  
depends at least partially on nuclear receptors



RNA virus


Hepatitis C virus

# HBV replication cycle and therapeutic targets




# Control of HBV genome transcription

- 3.2 kb circular DNA, partially double stranded
- 4 overlapping ORFs




- ① RNA 0.7 kb  
→ protein X
- ② RNA 2.1 kb
- ③ RNA 2.6 kb  
→ envelope glycoproteins: AgHBs
- ④ RNA 3.5 kb  
→ protein preCore  
→ protein Core polymerase  
→ pregenomic RNA



# **Study of FXR $\alpha$ on HBV replication**

- **Farnesoid X Receptor FXR**
  - Belongs to the NR1 family of nuclear receptors
  - ligands = bile acids (CDCA)
  - Regulates many genes of biliary salts synthesis and transport as well as glucose and lipid metabolism in the liver and intestine
  - Forms heterodimer with RXR $\alpha$
  - Consensus response element : AGGTCA .N.TGACCT (IR-1)



# FXREs in the EN2/pCore of HBV



Two putative FXREs in the Enhancer 2 and the core promoter


That may control the transcription of the pgRNA and HBV genome replication

# FXR $\alpha$ activates transcription from the HBV core promoter



# Effect of FXR $\alpha$ and RXR $\alpha$ on viral RNA synthesis

- Transfection of Huh-7  
p1.3xHBVwt  
pSG5-FXR $\alpha$  and/or -RXR $\alpha$
- Ligands of FXR $\alpha$  and/or RXR $\alpha$



FXR/RXR increases synthesis of the pregenomic RNA and viral DNA

# Conclusions for HBV

Ramière C. J Virol 2008

- FXR $\alpha$  can be added to the list of liver NR with PPAR $\alpha$  and HNF4 $\alpha$  that activate HBV replication
- Role of biliary salts in the natural history of hepatitis B ?
- Screening for small molecules modulating FXR activity

# Hepatitis C virus replication and FXR $\alpha$



HCV

- positive strand RNA
- *Flaviviridae* family




$d = 1.20 \text{ g/mL}$




Hepatitis C induces a specific metabolic syndrome:

- insulin resistance
- liver steatosis
- hypo-betalipoproteinemia



Hepatitis C viral particles in the blood of chronically infected patients are associated with lipoproteins

# Lipo-viral-particles (LVP)



$d < 1,06 \text{ g/mL}$

Andre et al. J Virol 2002


Andre et al. Semin Liver Dis 2005

Diaz et al. J Gen Virol 2006

Nielsen et al. J Virol 2006

Icard et al PLoSOne 2009

- Hybrid viral / lipoprotein particles :
  - Viral capsid
  - HCV RNA
  - Viral envelope proteins
  - Globular
  - Triglyceride rich
  - apoB-100 or apoB-48
- Liver and intestine : replication sites



Desforges et al. J Gen Virol 2004



# Bile acids and HCV


- **Enterohepatic circulation of BAs between the liver and intestine**  
the two replication sites of HCV  
*(Fischer et al. Clin Chim Acta 1996)*
- **High BA levels during hepatitis are marker of poor response to anti-HCV therapy**  
*(Lebovics et al. Dig Dis Sci 1997,  
Jorquera et al. J Gastroenterol Hepatol 2005)*
- **BAs are needed for *in vitro* replication of porcine Calicivirus**  
*(Chang et al. PNAS 2004)*




**hypothesis**

BAs might not be only consequence of hepatitis but rather metabolic factors favoring HCV replication and resistance to antiviral therapy

# Bile acids



- **Metabolic by-products of cholesterol,**  
dietary lipids and fat-soluble vitamins absorption
- **Hormones, 2 kinds of receptors:**
  - **Membrane receptor (TGR5)**
    - *Rapid intracellular signaling (cAMP)*
      - Inhibition of IFN pathway (*Calicivirus*)
  - **Nuclear receptors (FXR, PXR, VDR, CAR)**
    - *Control gene expression*




# HCV replicon system





- **Luciferase replicons**
  - ✓ Genotypes 1b (Con1), 1a (H77), 2a (JFH1)
  - ✓ negative control : mutation in pol (Rp-del)
- **Self replicating HCV RNA without production of viral particles in Huh-7**

# Bile acids enhance R1b replication




➤ Prolonged and sustained replication induced by DCA

# FREE bile acids enhance HCV replication




- Free bile acids induce a dose-dependent increase of the replication
  - Increase of the replication
  - No effect of conjugated bile acids
  - No effect of conjugated bile acids
- Effect of bile acids on HCV RNA replication  
is not mediated by the membrane receptor TGR5

# FXR agonists enhance HCV replication




- Within NR1 agonists, only FXR agonists enhance HCV RNA replication

# FXR antagonism inhibits HCV RNA replication




Chenodeoxycholic acid (CDCA)

natural FXR antagonist



- Bile acids inhibit replication when bile acid is added dependent fashion

# FXR silencing inhibits HCV RNA replication



No effect of bile acids in the absence of FXR

# Summary

Scholtes, J Hepatol 2008

- Free bile acids enhance HCV RNA replication
  - Dose-dependent effect
  - Mediated by FXR
  - Activation and inhibition of FXR modulates accordingly HCV RNA replication
  - Key factor for the growth of HCV

# Perspectives

- **Molecular mechanisms downstream of FXR**
  - role of PGC1 and coregulators ?
  - what metabolic pathways regulated by FXR are essential for HCV and why ?
  - Is the activity of FXR modified by HCV ?

# FXR, a therapeutic target for treating hepatitis C ?

- Several clinical trials targeting FXR are or have been conducted for metabolic diseases with GGST or synthetic molecule.
- A proof of concept clinical trial that FXR modulate in vivo HCV replication is scheduled early this summer with GGST in non responder patients (HCL; Service hépatologie, C. Trépo, F. Zoulim and CIC Lyon, F. Gueyffier).



Université Claude Bernard

# Thanks



Inserm unit 851,  
Lyon

Caroline Scholtes  
Christophe Ramière  
Olivier Diaz  
Martine Carreras

Vincent Lotteau

University of Heidelberg  
Ralf Bartenschlager

Institut Pasteur Lille  
Bart Staels



Institut national  
de la santé et de la recherche médicale



# FXR $\alpha$ binds as a heterodimer with RXR $\alpha$ to 2 REs in the EN2/core promoter region

CONS probe :


5'-GATCTCAAG**AGGTCAATTGACCT**TTTG - 3'

EN2 probe :


5'- GATCTCTGCA**ATGTCAACGACCG**ACCTTGA - 3'

Cp probe:


5'- GATCGATTAGATTAA**AGGTCTTGACT**AGGA - 3'




Mutations in either FXRE abolish the binding and activity of FXR



# HBsAg persistence under effective anti-pol therapy




# Modulation of HCV RNA replication by FXR is independent of IFN pathway



- Replication is still sensitive to IFN inhibition with similar IC<sub>50</sub>
- GGS has an additive effect to IFN

# FXR modulation on different HCV genotypes



- FXR controls the replication of both genotypes 1a and 1b
- No modulation of JFH-genotype 2a replication

# Perspectives 2

- HCV and metabolism crosstalk
  - Host metabolism influences HCV replication: FXR major metabolic regulator, HCV as a “metabolovirus”
  - HCV influences host metabolism:  
If HCV modifies FXR activity, what could be the impact on glucose and lipid metabolism as well as on liver injury ?

Expression of PPAR $\alpha$  and  $\gamma$ , LXR, SREBPs are modified by HCV (core, NS2).